Clinical Trial Update: To Evaluate the Efficacy and Safety of JT-003 add-on in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating JT-003 added to metformin and dapagliflozin in type 2 diabetes mellitus with inadequate control.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• JT-003

Snippet

Sponsor: Jeil Pharmaceutical Co., Ltd. | Conditions: Type 2 Diabetes Mellitus | Phase 3 | Status: UNKNOWN